<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02173912</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_CCA_102</org_study_id>
    <nct_id>NCT02173912</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of CJ-30059</brief_title>
  <acronym>CCA</acronym>
  <official_title>Open-label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetics and Safety Following Administration of CJ-30059 and Co-administration of Candesartan Cilexetil and Amlodipine Besylate in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the bioequivalence of the two treatments, the
      administration of CJ-30059 and the co-administration of candesartan cilexetil and amlodipine
      besylate, in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the plasma concentration-time Curve (AUC_last) of Amlodipine</measure>
    <time_frame>Upto 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the plasma concentration-time Curve (AUC_last) of Candesartan</measure>
    <time_frame>Upto 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of Amlodipine</measure>
    <time_frame>Upto 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of Candesartan</measure>
    <time_frame>Upto 72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration of Amlodipine</measure>
    <time_frame>Upto 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration of Candesartan</measure>
    <time_frame>Upto 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-lie of Amlodipine</measure>
    <time_frame>Upto 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-lie of Candesartan</measure>
    <time_frame>Upto 72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-dose crossover
Test: CJ-30059
Reference: Candesartan cilexetil 16 mg and Amlodipine besylate 10mg
Once daily Oral administration with at least 14 days of washout period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-dose crossover
Reference: Candesartan cilexetil 16 mg and Amlodipine besylate 10mg
Test: CJ-30059
Once daily Oral administration with at least 14 days of washout period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan cilexetil 16 mg and Amlodipine besylate 10mg (Reference)</intervention_name>
    <description>Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.
Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-30059 (Test)</intervention_name>
    <description>Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.
Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male volunteers in the age between 19 and 55 years old(inclusive)

          -  Body mass index (BMI) in the range of 18.5 to 27 kg/m2(inclusive)

          -  Available for the entire study period

          -  Understand the requirements of the study and voluntarily consent to participate in the
             study

        Exclusion Criteria:

          -  Subjects with a history of gastrointestinal diseases which might significantly change
             absorption, distribution, metabolism and excretion (ADME) of medicines

          -  Systolic blood pressure outside the range of 100 to 150 mmHg or diastolic blood
             pressure outside the range of 70 to 1000 mmHg for male subjects during screening

          -  Subject with symptoms of acute disease within 14days prior to study drug
             administration

          -  Subjects with a history of clinically significant allergies

          -  Subjects with a hereditary problems, for example, galactose intolerance, Lapp lactase
             deficiency or glucose-galactose malabsorption

          -  Subjects whose clinical laboratory test values are outside the accepted normal range.
             Especially, aspartate aminotransferase (AST) or alamin aminotransferase (ALT) &gt;1.5
             times of the Upper Normal Limit or total bilirubin &gt; 1.5 times of the Upper Normal
             Limit)

          -  History of drug abuse

          -  History of caffeine, alcohol, smoking abuse

               -  caffeine(coffee, tea, coke) or grapefruit juice &gt; 4 cups/day

               -  smoking &gt; 20 cigarettes/day

               -  alcohol &gt; 140 g/week

          -  Positive test results for Hepatitis B antibodies, Hepatitis C virus antibody, and
             Syphilis regain test

          -  Participation in any clinical investigation within 30 days prior to study drug
             administration

          -  Subjects with whole blood donation within 60 days, component blood donation within
             30days and blood transfusion within 30 days prior to study drug administration

          -  Subjects who are judged unsuitable by investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-wook Ko, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geun-Seog Song, PhD</last_name>
    <phone>82-2-6740-2440</phone>
    <email>kssong1212@cj.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eun-ji Kim</last_name>
    <phone>82-2-6740-2443</phone>
    <email>keunji@cj.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chaeyeong Lee</last_name>
    </contact>
    <investigator>
      <last_name>Jae-Wook Ko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2014</study_first_submitted>
  <study_first_submitted_qc>June 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <last_update_submitted>June 24, 2014</last_update_submitted>
  <last_update_submitted_qc>June 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

